secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0000950170-23-018779
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx Q1 2023: cash $533.6M; collaboration revenue $17.9M; net loss $27.3M
----------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $533.6M; expected to fund through BLA filing in H1 2025.
- Collaboration revenue $17.9M from Kite license agreement (vs $0); recognized on percentage-of-completion basis.
- R&D expenses $32.9M (up $14.8M), G&A $15.4M (up $7.4M); net loss $27.3M (vs $26.0M).
- Clinical milestones: completing iMMagine-1 enrollment, initiating iMMagine-2, and presenting longer-term Phase 1 data for CART-ddBCMA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000095017023018779/0000950170-23-018779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000095017023018779/aclx-20230508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-018779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer